A New Era in Multiple Myeloma: Is a Complete Cure Now a Realistic Goal?

Are Hopes Becoming Reality?

Long regarded as an incurable disease, multiple myelomahas reached a new threshold as of 2025. It may now be possible not only to extend life but, for some patients, even to eliminate the disease entirely. Hematology experts speaking at the recent “HematoAvanza” meeting organized by the European Society of Hematology (SEHH) stated that “A cure is possible.” In this article, we explore why we can now discuss a cure for multiple myeloma and which scientific advances are fueling this hope.

🎯 Multiple Myeloma: From an Incurable Disease to the Potential for a Cure

Prof. María-Victoria Mateos (Salamanca University Hospital, Spain) described a paradigm shift: “We can now use the word ‘cure’ for some patients with multiple myeloma.” Particularly through early diagnosis, innovative medicines, and precise diagnostic tools, some patients can reach the life expectancy expected for their age and sex, and some may even have periods during that time when they do not need treatment.

“A functional cure, or a chronic disease state that does not require treatment, is now a realistic goal.” — Prof. Mateos

⚠️ Challenges: Older Age, Heterogeneity, and Clonal Evolution

• Because most patients are >65 at diagnosis, age-related challenges remain important.
• Genetic and biological heterogeneity and clonal evolution lead to the emergence of treatment-resistant subclones.
• For this reason, multidrug combinations and early intervention increase the chance of a cure.

🧪 Scientific Advances: MRD Negativity and Next-Generation Immunotherapies

✅ Minimal Residual Disease (MRD) Negativity

• MRD negativity has now become a central goal in multiple myeloma treatment.
• The inability to detect disease cells even with the most sensitive techniques is a strong indicator of prolonged survival.
• The FDAnow accepts MRD negativity as a primary endpoint in new drug approvals. The EMA is pursuing a similar process.

📊 Survival rates are exceptionally high in patients with sustained MRD negativity.

🔬 Innovative Treatments: CAR-T Cells and Bispecific Antibodies

• CAR-T cell therapies and bispecific antibodies have gone far beyond conventional chemotherapy.
• These agents are now beginning to be used even in newly diagnosed patients.
• These advances have made the “goal of a cure” realistic in multiple myeloma for the first time.

📌 The PERSEUS Study: More Than 17 Years Without Progression

• Daratumumab + Bortezomib + Lenalidomide + Dexamethasone + Autologous Transplantation in combination:
• Median PFS: 17 years
• In some patients with a favorable prognosis, more than 20 years
• Even in patients who are not transplant candidates, PFS can reach 9–11 years .

For the first time in multiple myeloma, these data make it possible to use the term “effective cure” .

🧩 Early Intervention: A Game-Changing Effect in Smoldering Myeloma

• In high-risk asymptomatic patients, early treatment with lenalidomide:
• Delays progression by up to 7 years
• Produces sustained MRD negativity in 30% of patients

These findings suggest that early intervention strategies could replace the “watch-and-wait” approach.

🏥 National Strategies and Access: The Example of Spain

• Spain's National Advanced Therapies Plan is being restructured to ensure equitable access to these treatments across the country.
• Recently, 3 additional hospitals were accredited as advanced therapy centers.
• Such steps aim to reduce inequalities in access to treatment and extend the goal of a “cure” to broader patient populations.

🔭 Looking Ahead: 2025 and Beyond

• MRD-negative diseaseis now both a target for new treatments and a licensing criterion.
• The natural course of multiple myeloma is changing as immunotherapies play an increasing role.
• A cure is still not guaranteed for every patient; however, functional disease-free living is now a real option.

🧠 Conclusion: Hope Is Becoming Reality in Multiple Myeloma

The year 2025 may go down in history as a turning point in multiple myeloma treatment. Through MRD negativity, early treatment, cellular therapies, and innovative medicines, patients are not only living longer: some can be completely cured.

🟢 Supporting these advances through patient education, treatment guidelines, and public policy is critical to making the goal of a cure for multiple myeloma a reality.